Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Managed Care February 2005 Mark Zitter	Managing Drugs for Rare Genetic Diseases: Trends and Insights Evaluates recent trends and challenges in health system management of exceedingly rare genetic diseases, from the perspective of the manufacturer, managed care organization, physician, and actuary.
Pharmaceutical Executive September 1, 2008 Jeffrey S. Aronin	The Orphan Opportunity The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains
Pharmaceutical Executive February 1, 2011 Jill Wechsler	The Building Block of Drug Discovery With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?
Managed Care September 2004 Thomas Morrow	Orphan Drug Act Treatments Deserve Full Insurance Coverage An important federal law encourages development of drugs for populations so small that the market would otherwise ignore them. Should they not then be covered?
Chemistry World June 8, 2015 Rebecca Trager	NIH drug manufacturing unit shut down The halt could potentially affect 46 clinical trials, and about 250 patients who are either receiving, or about to receive, products manufactured at the facility.
Chemistry World September 11, 2012 Maria Burke	Orphan drugs set for 'tremendous growth' A new report by Thomson Reuters offers clear confirmation that developing drugs for rare, or orphan, diseases is economically attractive, despite the smaller patient pool.
The Motley Fool March 3, 2011 Ryan McBride	With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players.
Pharmaceutical Executive October 1, 2011	Patient Advocacy: The Last 30 Years The rise of advocacy groups has helped patients find their voice, but the power to change health profiles remains an elusive goal.
Bio-IT World August 2005 Maureen McDonough	Mining Clinical Data with i2b2 How do you conduct clinical research in the genomic era? A team of Harvard scientists is building an answer from the ground up. The $20-million IT project will extract information from the private medical files of some 2.5 million people.
Pharmaceutical Executive October 1, 2011 Jennifer Ringler	The "Mother" of Invention Abbey Meyers, Founder, National Organization of Rare Disorders, believes patient empowerment can foster change.
Bio-IT World June 2005 Nancy J. Kelley	Building Centers of Excellence in Translational Medicine New approaches to drug development that will be more effective in translating research to patient delivery will require the design and construction of new facilities that foster new ways of working among larger, multidisciplinary, teams of scientists and medical professionals in biology, chemistry, physics, mathematics, engineering, computer science, and, of course, information technology.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
Chemistry World December 24, 2015 Rebecca Trager	US research agencies finally get their new budgets The US fiscal year 2016 appropriations, signed by President Obama on 18 December, provide $148.6 billion for federal research and development, an increase of 8.1% above current levels
Managed Care September 2005	Some Elderly Not Helped by Guidelines Generally accepted clinical practice guidelines (CPGs) offer little help to physicians who are treating elderly patients with multiple chronic conditions, according to a recent study.
The Motley Fool September 2, 2010 Brian Orelli	Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases.
Bio-IT World August 13, 2003 Wendy Wolfson	Orphan Drugs: For Love or Money? Entrepreneurs organize to work toward cures for rare 'orphan' diseases.
Pharmaceutical Executive November 1, 2011 Elizabeth O. Coulton	Clinical Trial Issues Not Just Black and White The selection of clinical trial participants must meld with the changing demographics of America if industry is to improve medicines that work for patients.
The Motley Fool October 16, 2007 Brian Orelli	Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note.
Managed Care November 2005 Patrick Mullen	This Biologics Industry Spokesman Knows That Health Plans Can Only be Won Over by the Financial Argument. Biotech's focus is expanding from products that treat relatively rare diseases to treatments for conditions that affect much larger populations, including various cancers, diabetes, rheumatoid arthritis, and asthma because of health plan costs.
Chemistry World June 25, 2015 Rebecca Trager	NIH plan to get drug development unit back online The NIH has set out key milestones in its plan, including training and re-training personnel in good manufacturing practice regulations by August.
Reason June 2005 Kerry Howley	Scientists for Sale Innovation vs. ethics: Scientists at the NIH have discovered many things over the years, but evidently they haven't yet found a way to balance innovation and objectivity.
Pharmaceutical Executive October 1, 2011 Jill Wechsler	Guiding a Revolution in Science Francis Collins led the genomic revolution as director of the International Human Genome Project and director of the National Human Genome Research Institute (NHGRI) at the NIH from 1993 to 2008.
Pharmaceutical Executive June 1, 2006 Nancy Dreyer	Personalized Medicine Meets the Real World A wave of genomic medicines is coming down the pipeline, and they're going to be expensive. Can companies prove they're worth it? Maybe: but the claims payers seek aren't coming from traditional clinical trials.
Bio-IT World November 14, 2003 Kathy Ordonez	Targeted Medicine via Molecular Diagnostics Using diagnostics to select and deselect target populations for drug therapy will enable life scientists to make more effective medicines.
Information Today July 2, 2013	Thomson Reuters Offers Clinical Trial Intelligence Solutions These solutions improve clinical trials, speed up product development and release, and help professionals strengthen portfolios and R&D strategy.
Pharmaceutical Executive April 1, 2012 Feam & Lagus	Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help.
Managed Care June 2006 Thomas Morrow	Pompe Disease Therapy Presents Coverage Challenge Although Myozyme is approved for the infantile form of Pompe disease, it is logical to extend coverage to patients with the late onset form.
Pharmaceutical Executive February 1, 2007 John Smith	Public Relations: Beef Up Clinical Trial Numbers Web-based public relations can make the difference in clinical-trial recruitment.
BusinessWeek March 14, 2005 Arnst & Barrett	Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments
Managed Care June 2003	Effectiveness of review process in eye of beholder From January 1999 to December 2000, 263 independent medical reviews were conducted in California as a result of patients trying to overturn coverage decisions by health plans. The Institute of Medical Quality surveyed those patients to obtain their opinions on the review process.
Managed Care March 2007	Harvard Study Endorses Value-Based Insurance Design A new study shows that employers and other payers who are designing health benefits should make cost-effective treatments free or low-cost for patients and charge more for less cost-effective alternative treatments.
Bio-IT World August 13, 2003 John Rhodes	Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert.
Pharmaceutical Executive September 1, 2013 Jill Wechsler	Biopharma Innovation in Trouble? Regulators, sponsors seek more productive research strategies.
Pharmaceutical Executive January 1, 2013 Al Topin	The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author.
Chemistry World February 6, 2015 Rebecca Trager	US funder mulls new emeritus award The US National Institutes of Health is exploring a new grant mechanism for emeritus faculty that would let senior investigators exit their NIH research grant supported role.
The Motley Fool February 28, 2011 Brian Orelli	Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on.
Pharmaceutical Executive November 1, 2012 Sue Barrowcliffe	Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options.
Geotimes November 2004	Open Access: Open Debate? Imagine any U.S. citizen having free and open access to research funded with tax dollars. That possibility could be closer to reality than ever before, but Congress must first address some important concerns
Pharmaceutical Executive March 1, 2013 Ken Getz	Building Clinical Trial Awareness for Patients: Why Not Try the Pharmacist? The author explains how building a stakeholder outreach agenda around the community pharmacist can lead to a better outcome in managing the complex ins and outs of a trial protocol.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
Pharmaceutical Executive September 1, 2011 Richard Barker	Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
Chemistry World January 23, 2015 Rebecca Trager	Obama talks up research, announces personalized medicine initiative President Obama has highlighted the importance of research and innovation to the health of the US economy and its citizens.
Chemistry World June 2, 2015 Rebecca Trager	NIH-funded principal investigators fell sharply in 2010 A former senior leader at the US National Institutes of Health has found what he calls a 'startling' decline in the number of principal investigators funded by the agency from between 2010 and the present day.
AskMen.com Joshua Levine	Selling Your Body To Science Have you ever thought about the number of voluntary patients who basically sell their bodies to clinical trials in the name of science? Well, the number is staggering and it can reach well into the thousands. The main reason being the large paycheck that comes with the job.
Pharmaceutical Executive June 1, 2012 Jill Wechsler	Innovation and Collaboration A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market.
Information Today June 16, 2015	NIH Plans for the Future of the National Library of Medicine The National Institutes of Health's director, Francis S. Collins, approved the proposed strategic plan for the National Library of Medicine.
The Motley Fool May 28, 2004 Charly Travers	Don't Be a Biotech Gambler Stand on solid ground by learning to assess the value of future drug programs. Investing in biotechs -- rather than simply speculating in the sector -- requires a solid assessment of how much a company's drug programs could be worth.
Bio-IT World January 21, 2005 Salvatore Salamone	Tackling the Biobank Data Challenge To be successful, biobanks must ensure that the information they collect gets maximum use by others. A host of legal, financial, and intellectual property issues must be addressed from the beginning.
Bio-IT World March 10, 2003 Dawn Stover	E-Recruitment: Trial by Wire Online databases are helping patients find clinical trials -- but e-recruitment is no panacea for participant shortages.